After years of regulatory woes and drug shortages, Boehringer Ingelheim is calling it quits for Ben Venue, planning to shut down its contract manufacturing arm by year's end and lay off about 1,100 workers.
Counting on a boom in the Asian demand for injectables, contract manufacturer West Pharmaceutical Services has opened the doors on a nearly 40,000-square-foot facility.
Contract manufacturer Capsugel is pouring millions into three facilities around the world, looking to bolster its bandwidth in soft gelatin and liquid-fill hard capsules.
U.K. contract manufacturer Aesica is counting on a bullish market for solid dose diabetes drugs, and the company has poured $48 million into one of its plants to meet the demand.
Catalent has partnered up with Supernus Pharmaceuticals to supply the generics maker's extended-release epilepsy drug, a product the companies say has a chance to snag a share of a big market.
Contract manufacturer Patheon is still reaping the benefits of its high-dollar buyout of Banner Pharmacaps, wrapping up the integration process and reporting a 30.4% leap in quarterly profits.
Contract manufacturer Capsugel has signed a deal to buy Oregon's Bend Research, planning to fold that company's oral drug delivery technology into its growing innovative dosing business.
After months of regulatory woes and declining demand, Lonza is planning to cut two-thirds of its staff at a Massachusetts biologics plant, part of the CMO's overall effort to restructure and adapt to a changing market for commercial manufacturing.
The problem this time relates to a filling line at the plant that manufactures two combination vaccines, Daptacel and Pentacel.
After months of fretting over API capacity, Boehringer Ingelheim is planning to shutter en masse its Petersburg, VA, commercial plant, putting 240 employees out of a job.